# A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

> **NCT02423902** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alaunos Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** Ad-RTS-hIL-12
- **DRUG:** Veledimex

## Key facts

- **NCT ID:** NCT02423902
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-18
- **Primary completion:** 2016-07-19
- **Final completion:** 2016-07-19
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423902, "A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02423902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*